Long-Term Survival in Primary Plasma Cell Leukemia after Therapy with VAD, Autologous Blood Stem Cell Transplantation and Interferon-Alpha

Panizo, Carlos; Rifón, J.; Rodríguez-Wilhelmi, Pablo; Cuesta, B; Rocha, Eduardo

doi:10.1159/000040952

Cited by 14 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Intensification of therapy using high dose melphalan was reported in PCL around the same time as application of this regime in multiple myeloma. 11 There have been several case reports [12][13][14][15][16][17] as well as descriptions of one 2 and five 1 patients in two previously reported series of patients with PCL describing the value of melphalan or other high-dose therapy when combined with autologous transplantation. In general, patients received induction with aggressive combination chemotherapy and the median survival after autografting ranged from 3 to 59 months.…”

Section: Discussionmentioning

confidence: 99%

Primary plasma cell leukemia and autologous stem cell transplantation

Drake

Iacobelli²,

Biezen³

et al. 2010

Haematologica

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Primary plasma cell leukemia and autologous stem cell transplantation

Drake

Iacobelli²,

Biezen³

et al. 2010

Haematologica

View full text Add to dashboard Cite

“…Kürzlich wurde über die erfolgreiche Behandlung mit Fludarabin berichtet [9]. In anderen Fallbeschreibungen wurden intensivierte Therapie-Programme wie Hochdosis-Cyclophosphamid mit Etoposid oder Hochdosis-Melphalan [10] in Kombination mit peripherer Stammzell-Transplantation erfolgreich eingesetzt. Wir behandelten zwei Patienten mit primärer Plasmazell-Leukämie erfolgreich nach dem BMF-Protokoll für B-Zell Leukämien.…”

Section: Therapieunclassified

Diagnostik und Therapie der Plasmazell-LeukÃ¤mie

Jehn¹

2002

Tumordiagn u Ther

View full text Add to dashboard Cite

DiagnoseDie Plasmazell-Leukämie ist eine Variante des multiplen Myeloms, welche sich als Leukämie repräsentiert. Sie ist eine seltene Erkrankung und macht 0,3 % aller Leukämien und 2 -4 % aller Myelome aus. Die Diagnose setzt voraus, dass die betroffenen Patienten mehr als 20 % Plasmazellen im Differenzial-Blutbild und absolut wenigstens 2000 Plasmazellen/l haben. Man unterscheidet eine primäre und eine sekundäre Form. Letztere stellt eine finale, leukämische Transformation eines meist Jahre zuvor diagnostizierten multiplen Myeloms dar. Etwa 60 % aller Patienten mit Plasmazell-Leukämie haben eine primäre Form.Chromosom 14 q 32 Translokationen, besonders t (6;14) (p 21.1; SchlüsselwörterPlasmazell-Leukämie · Vorkommen · Diagnose · Therapie Abstract Plasma cell leukemia is a rare disease. Important for diagnosis is the presence of more than 20 % plasma cells in the differential blood count or at least 2 10 6 plasma cells. In about 60 %, cytogenetics are helpful for diagnosis. There is a primary and a secondary form. Most commonly used for treatment is a combination of melphalan and prednisone. Median survival is 7 months for the primary and 2 months for the secondary form.

show abstract

“…A literature review showed only one case of plasma cell leukaemia with extended survival after autologous bone marrow transplantation (Kun‐Huei Yeh et al. , 1995) and a few other cases with variable results (Sajeva et al ., 1996; Majolino et al ., 1998; Sion et al ., 1998; Leleu et al ., 1999; Panizo et al ., 1999). In one report (Koskela et al ., 1998), a patient with multiple myeloma developed plasma cell leukaemia only 3 months after autologous PBSCT.…”

Section: Discussionmentioning

confidence: 99%

Low cost autologous peripheral blood stem cell transplantation performed in a municipal hospital for a patient with plasma cell leukaemia

Ghosh

Gosavi²,

Pathare³

et al. 2002

Clinical &Amp; Laboratory Haematology

View full text Add to dashboard Cite

Autologous peripheral blood stem cell transplantation (PBSCT) is a costly procedure. In India, the cost varies from US$20000 to 25000 and most patients cannot afford it. Using several cost-cutting measures, we were able to treat a patient with plasma cell leukaemia by autologous PBSCT. A 42-year-old-male presented with plasma cell leukaemia. He was treated with VAD therapy, followed by high-dose cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) for mobilization of peripheral blood stem cells. The patient was conditioned with high dose melphalan, followed by autologous PBSCT. The procedure was performed in a municipal hospital in which there was no prior experience with stem cell transplantation. Costs were reduced by: (i) using oral medication whenever possible; (ii) having a relative of the patient prepare his food under medical guidance; (iii) starting G-CSF on day 7 rather than on day 1; (iv) short-term storage of the PBSC in an ordinary refrigerator at 4 degrees C without cryopreservation; (v) infusing a large number of CD34+ cells, which shortened the time to engraftment; (vi) delegating many of the functions of a marrow transplant nurse to a resident physician. The cost of transplantation was thereby reduced to about US$ 6000, with successful engraftment by day +13. The patient remained in remission for 7 months, after which he relapsed and was treated with chemotherapy and electron beam radiation to the skin.

show abstract

Long-Term Survival in Primary Plasma Cell Leukemia after Therapy with VAD, Autologous Blood Stem Cell Transplantation and Interferon-Alpha

Cited by 14 publications

References 11 publications

Primary plasma cell leukemia and autologous stem cell transplantation

Primary plasma cell leukemia and autologous stem cell transplantation

Diagnostik und Therapie der Plasmazell-LeukÃ¤mie

Low cost autologous peripheral blood stem cell transplantation performed in a municipal hospital for a patient with plasma cell leukaemia

Contact Info

Product

Resources

About